EP2199298A1 — Sirna silencing of Apolipoprotein B
Assigned to Protiva Biotherapeutics Inc · Expires 2010-06-23 · 16y expired
What this patent protects
The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence apoB expression and methods of using such nucleic acid-lipid particles to silence apoB expression.
USPTO Abstract
The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence apoB expression and methods of using such nucleic acid-lipid particles to silence apoB expression.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.